相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3-and 6-month response rates in trials of biological agents
M. Boers
ANNALS OF THE RHEUMATIC DISEASES (2010)
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals
Maarten Boers
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
TNF-alpha Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
Antonio Marchesoni et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis
B. Kuriya et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
K. Visser et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative
K. Visser et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Methotrexate: the gold standard without standardisation
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study
I. Hafstroem et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Choice of Second-Line Disease-Modifying Antirheumatic Drugs After Failure of Methotrexate Therapy for Rheumatoid Arthritis: A Decision Tree for Clinical Practice Based on Rheumatologists' Preferences
Bruno Fautrel et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Defining Remission in Rheumatoid Arthritis: Results of an Initial American College of Rheumatology/European League Against Rheumatism Consensus Conference
Lilian H. D. van Tuyl et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
The use of data from early arthritis clinics for clinical research
Daniel Aletaha et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2009)
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists
John D. Isaacs
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis
Marlies Blom et al.
JOURNAL OF RHEUMATOLOGY (2009)
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
R. F. van Vollenhoven et al.
LANCET (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Prognostic factors in rheumatoid arthritis in the era of biologic agents
Alla Skapenko et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
The Disease Activity Score and the EULAR Response Criteria
Jaap Fransen et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
Martin Soubrier et al.
RHEUMATOLOGY (2009)
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial
L. H. D. van Tuyl et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
B. Saleem et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
D. Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
ARTHRITIS AND RHEUMATISM (2008)
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2008)
Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis
Annette H. van der Helm-van Mil et al.
ARTHRITIS AND RHEUMATISM (2008)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis
P. Verschueren et al.
RHEUMATOLOGY (2008)
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
Josef S. Smolen et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
E. H. S. Choy et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
D. Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis
Bruno Fautrel et al.
JOINT BONE SPINE (2007)
Treatment of early rheumatoid arthritis
Patrick Durez et al.
ARTHRITIS AND RHEUMATISM (2007)
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
S. M. M. Verstappen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2007)
Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
M. Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care
Daniel Aletaha et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
A. E. van der Bijl et al.
ARTHRITIS AND RHEUMATISM (2007)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis - A double-blind, randomized, placebo-controlled trial
Henrike van Dongen et al.
ARTHRITIS AND RHEUMATISM (2007)
A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis - How to guide individual treatment decisions
Annette H. M. van der Helm-van Mil et al.
ARTHRITIS AND RHEUMATISM (2007)
Early rheumatoid arthritis: strategies for prevention and management
Bernard Combe
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
B. Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases:: a review
E. U. Sumer et al.
BIOMARKERS (2006)
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
B. Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs - A one-year randomized, placebo-controlled study
M. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2006)
Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
D Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The definition and measurement of disease modification in inflammatory rheumatic diseases
D Aletaha et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
The benefit of low-dose glucocorticoid treatment in early rheumatoid arthritis may outweigh the risk: Comment on the editorial by Harris
JWG Jacobs et al.
ARTHRITIS AND RHEUMATISM (2006)
Molecular imaging:: novel tools in visualizing rheumatoid arthritis
A Wunder et al.
RHEUMATOLOGY (2005)
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years - A multicenter, double-blind, placebo-controlled trial
S Wassenberg et al.
ARTHRITIS AND RHEUMATISM (2005)
Comparison of different definitions to classify remission and sustained remission:: 1 year TEMPO results
D van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Biomarkers for diagnosing and monitoring autoimmune diseases
HE Prince
BIOMARKERS (2005)
Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
H Mäkinen et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
D Aletaha et al.
ARTHRITIS AND RHEUMATISM (2005)
Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index
JC Cole et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis
FC Breedveld et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Therapeutic strategies in early rheumatoid arthritis
JS Smolen et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2005)
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey
D Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs -: Five-year experience from the FIN-RACo study
M Korpela et al.
ARTHRITIS AND RHEUMATISM (2004)
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial
HA Capell et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Radiography as primary outcome in rheumatoid arthritis:: acceptable sample sizes for trials with 3 months' follow up
K Bruynesteyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
Glucocorticoids in the treatment of early and late RA
JWJ Bijlsma et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis
DL Conn et al.
CURRENT OPINION IN RHEUMATOLOGY (2003)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
JS Smolen et al.
RHEUMATOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Rheumatoid arthritis - Treatment of early disease
M Boers
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2001)
Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis
AC Verhoeven et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
分享论文
